نتایج جستجو برای: relapsed hodgkin lymphoma
تعداد نتایج: 117560 فیلتر نتایج به سال:
a case of primary malignant non-hodgkin's lymphoma of the breast is reported. this is the first well-documented case of breast lymphoma in our institution and also in iran. the diagnosis of primary breast lymphoma requires the presence of lymphomatous infiltration in close ass, tissue in patients with neither previous lymphoma nor concurrent lymphoma in another site. there is no definite c...
INTRODUCTION This study is aimed to assess the prevalence and characteristics of head and neck lymphoma in a defined group of an Iranian population. MATERIALS AND METHODS In this retrospective study, 126,450 biopsy reports from two referral Pathology Departments, (Tehran, the capital of Iran) were evaluated. In cases with head and neck lymphoma, other variables such as age, sex, specific loca...
Rituximab is a chimeric monoclonal antibody targeting the B cell antigen CD20. Since its first approval for clinical use in 1997, rituximab has become an inherent part of the treatment of CD20-positive lymphoma. In previously untreated non-Hodgkin lymphoma (NHL) conventional chemotherapy supplemented by rituximab (R-chemotherapy) was shown to be more effective than chemotherapy alone. This hold...
Low-grade rash may occur with lenalidomide, rituximab, or their combination (R) in non-Hodgkin lymphoma (NHL). From our phase II study of R in previously untreated indolent lymphoma (n=110), 52 (47%) patients had rash, which was associated with pruritus in 22 (42%). Worst grade 1, 2, and 3 rash was found in 19%, 21%, and 7%, respectively. Grade 1/2 rash was effectively managed with observation,...
Correspondence: Holger Schulz pioh – Praxis internistischer Onkologie und Häematologie Kölnerstr. g, 50226, Frechen, Germany Tel +49 02234-99959-0 Fax +49 02234-99959-25 Email [email protected] Abstract: Rituximab is a chimeric monoclonal antibody targeting the B cell antigen CD20. Since its first approval for clinical use in 1997, rituximab has become an inherent part of the treatment of CD20-po...
Despite improvements over the past decade in the overall survival of patients with indolent non-Hodgkin lymphomas, these lymphomas remain largely incurable with standard therapies. Immunochemotherapy with rituximab-based regimens has become a well-established standard of care in the primary and relapsed disease settings. The role of hematopoietic stem cell transplantation in indolent lymphoma h...
8531 (2009). Monoclonal antibody therapy for classical Hodgkin lymphoma Review: Clinical Trial Outcomes future science groupClin. Invest. (2013) 3(9)90932 Thertulien R, Frankel AE, Evens AM et al. APhase I, open-label, dose-escalation,multidose study of MDX-1401 (defucosylatedhuman antiCD30 monoclonal antibody) inpatients with CD30-positive refractory/relapsed Ho...
The treatment of transformed indolent lymphoma (TRIL) often includes salvage chemotherapy (SC) and autologous stem cell transplant (ASCT). NCIC CTG LY12 is a randomized phase 3 trial comparing gemcitabine, dexamethasone, and cisplatin (GDP) with dexamethasone, cytarabine, and cisplatin (DHAP) before ASCT. This analysis compares the results of SC and ASCT for TRIL with de novo diffuse large B-ce...
abstract objective the incidence of childhood cancer has been increasing nearly one percent per year for the past two decades. leukemia and lymphoma are the most common types of childhood cancers. this study assessed the relation between environmental factors (hydrocarbon, agricultural toxin, insecticide) and leukemia/lymphoma in children, which was evaluated by the frequency of the parents’ ha...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید